- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Threshold Pharmaceuticals Provides Q4 and 2012 Financial Update
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) has released its fourth quarter and year-end 2012 financial results and operational update. According to the company, its revenue for the fourth quarter was $2 million and its annual income was $5.9 million.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) has released its fourth quarter and year-end 2012 financial results and operational update. According to the company, its revenue for the fourth quarter was $2 million and its annual income was $5.9 million.
As quoted in the press release:
Net income for the fourth quarter ended December 31, 2012 was $28.4 million, which included the operating loss of $6.0 million and non-cash income of $34.4 million related to changes in the fair value of the Company’s outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2012 was $71.1 million, which included the operating loss of $20.0 million and non-cash expense of $51.2 million related to changes in the fair value of the Company’s outstanding and exercised warrants.
Click here to read the full Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.